V. 7-80) PA		DEPARTMENT OF COMMERCE ADEMARK OFFICE	•	Atty. Docket No. (Options	al)	Application	Number	
LIST OF PRIOR ART CITED BY APPLICANT  (Ese several sheets if necessary)			18086 (PC27339A)		10/533,017			
								0 2 100
, "		•		Maria Cristina Geron Filing Date	ni, et al.	Group Art U	init	
CNT & TRA	<i>5</i> /		`	April 28, 2005		Unassigne		
		,	FOREIGN	PATENT DOCUMEN	NTS .			,
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS	LATION
		-					YES	NO
/M.F./	1	088 900 A1	4/4/01	EPO			7	
/M.F./	W	VO 01/58444 A1	8/16/01	PCT			1	
/M.F./	W	VO 02/088714 A2	11/7/02	PCT		1.	1	
							<del></del>	
	<u> </u>			7.0077.000	ing Author Tide	Data Bantinant	Pages Ftc	1
'M.F./		PNU-152243A) and i	MS-MS Del its 13-OH M	termination of Nemor Metabolite (PNU-1550 Analysis, 30:377-389	ubicin (Methos 151A) in Hum	oxymorphol	inyldoxo	rubicin
/M.F./		PNU-152243A) and in Pharmaceutical and in the second secon	MS-MS Det its 13-OH M Biomedical	termination of Nemor letabolite (PNU-1550 Analysis, 30:377-389	ubicin (Methos 51A) in Hum (2002)	oxymorphol an Plasma'',	inyldoxo Journal	rubicin of
/M.F./ /M.F./		PNU-152243A) and in Pharmaceutical and in the second secon	MS-MS Detaits 13-OH MBiomedical	termination of Nemor Metabolite (PNU-1550 Analysis, 30:377-389 The Erythromycin Brea	ubicin (Methos 51A) in Hum (2002)	oxymorphol an Plasma'',	inyldoxo Journal	rubicin of
		PNU-152243A) and in Pharmaceutical and in Rivory L.P. et al., "O Clinical Cancer Rese	MS-MS Defits 13-OH MBiomedical optimizing the earch, 6:348	termination of Nemor Metabolite (PNU-1550 Analysis, 30:377-389 The Erythromycin Brea	ubicin (Methos 51A) in Hum (2002) th Test for U	oxymorphol an Plasma", se in Cancer	inyldoxo.  Journal  Patients	rubicir of
/M.F./		PNU-152243A) and in Pharmaceutical and a Rivory L.P. et al., "O Clinical Cancer Reservivory L.P. et al., "Heatients Who Have a Hirth J. et al., "The E	MS-MS Detaits 13-OH MBiomedical eptimizing the arch, 6:348 depatic Cyton Acute-Pha	termination of Nemor Metabolite (PNU-1550 Analysis, 30:377-389 the Erythromycin Brea 10-3485 (2000) chrome P450 3A Dru	ubicin (Methos 1A) in Hum (2002) th Test for Use g Metabolism a Journal of Comme CYP3A4	oxymorphol an Plasma", se in Cancer is Reduced	Patients	rubicin of ,, er 0 (200
/M.F./ /M.F./		PNU-152243A) and in Pharmaceutical and a Rivory L.P. et al., "O Clinical Cancer Researched Rivory L.P. et al., "He Patients Who Have a Hirth J. et al., "The E Clearance", Clinical Martinez C. et al., "E	MS-MS Decits 13-OH MBiomedical  ptimizing the arch, 6:348  depatic Cyton Acute-Phane  effect of an I  Cancer Reserve	termination of Nemor Metabolite (PNU-1550 Analysis, 30:377-389 the Erythromycin Brea 10-3485 (2000) chrome P450 3A Dru ase Response", British	ubicin (Methos 1A) in Hum (2002)  th Test for Use g Metabolism a Journal of Come CYP3A4 (2000)	oxymorpholian Plasma", se in Cancer a is Reduced Cancer, 87(3). Activity on activity in History	Patients' in Cance ):277-28	rubicir of , , er 0 (200
/M.F./		PNU-152243A) and in Pharmaceutical and a Rivory L.P. et al., "O Clinical Cancer Researched Rivory L.P. et al., "He Patients Who Have a Hirth J. et al., "The E Clearance", Clinical Martinez C. et al., "E Cancer: Implications Quintieri L. et al., "In	MS-MS Detats 13-OH MBiomedical  reptimizing the arch, 6:348  depatic Cyton Acute-Phane  affect of an Incancer Reservation of the Cancer Thanks of the Cancer	termination of Nemor Metabolite (PNU-1550 Analysis, 30:377-389 the Erythromycin Breat 0-3485 (2000) throme P450 3A Drugase Response", British Individual's Cytochromearch, 6:1255-1258 (2016) throme P450 3A Drugase Response", British Individual's Cytochromearch, 6:1255-1258 (2016) thromearch, 6:1255-1258 (2016)	ubicin (Methos 1A) in Hum (2002)  th Test for Under the Test for Under the CYP3A4 (2000)  and CYP3A And of Cancer the CYP3A AN	oxymorpholian Plasma", se in Cancer is Reduced Cancer, 87(3) Activity on activity in High 87(6):681-6	Patients' in Cance 2:277-28  Docetaxe  uman Co 586 (200)	rubicir of , , er 0 (200)

NEV. 7-80) PATENT	U.S. DEPARTMENT OF COMMERCE AND TRADEMARK OFFICE	Atty. Docket No. (Optional)	Application Number			
	LIST OF PRIOR ART ITED BY APPLICANT	18086 (PC27339A)	10/533,017			
(Use	e several sheets if necessary)		·			
		Applicant(s) Maria Cristina Geroni, et al.				
		Filing Date April 28, 2005	Group Art Unit Unassigned			
	OTHE	R DOCUMENTS (Including Author,				
/M.F./		family: Update on New Sequen	nces, Gene Mapping, Accession			
/M.F./	de Waziers et al., "Cytochrome P450 Isoenzymes, Epoxide Hydrolase and Glutathione Transferases in Rat and Human Hepatic and Extrahepatic Tissues", <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 253(1):387-394 (1990)					
/M.F./	Chang T.K.H. et al., "Differential Activation of Cyclophosphamide and Ifosphamide by Cytochromes P-450 and 3A in Human Liver Microsomes", Cancer Research, 53:5629-5637 (1993)					
/M.F./	Kivistö K.T. et al., "The Role of Human Cytochrome P450 Enzymes in the Metabolism of Anticancer Agents: Implications for Drug Interactions", British Journal of Clinical Pharmacology, 40:523-530 (1995)					
/M.F./	Shimada T. et al., "Interindividual Variations in Human Liver Cytochrome P-450 Enzymes Involved in the Oxidation of Drugs, Carcinogens and Toxic Chemicals: Studies with Liver Microsomes of 30 Japanese and 30 Caucasians", The Journal of Pharmacology and Experimental Therapeutics, 270(1):414-423 (1994)					
/M.F./	Murray A. et al., "Study of the Immunohistochemistry and T Cell Clonality of Enteropathy-Associated T Cell Lymphoma", American Journal of Pathology, 146(2):509-519 (1995)					
/M.F./	Waxman D.J. et al., "P450 Gene Induction by Structurally Diverse Xenochmeicals: Central Role of Nuclear Receptors CAR, PXR, and PRAR", Archives of Biochemistry and Biophysics, 369(1):11-23 (1999)					
/M.F./	Geroni C. et al., "Methoxymorpholinyldx (FCE23762, PNU152243) Metabolism: Isolation, Structure Identification, and Biological Characterization of Active Metabolites", Proceedings of the American Association for Cancer Research, 38:234 (1997)					
XAMINER	/Meghan Finn/	DATE CONSIDERED 08/01/20	07			
EVAMINED. I.	nitial if reference considered, whether or not citation		· · · · · · · · · · · · · · · · · · ·			